跳至主要内容
临床试验/NCT04584424
NCT04584424Unknown不适用

Prognostic Factors and Outcomes of COVID-19 Cases in Ethiopia: Multi-Site Cohort Study

Ethiopian Public Health Institute1 个研究点 分布在 1 个国家目标入组 6,390 人开始时间: 2020年10月30日最近更新:
适应症

试验速览

阶段
不适用
入组人数
6,390
试验地点
1
主要终点
Number of patients survival or death

研究概览

简要总结

The aim of the study will be to determine the epidemiological and clinical features of COVID-19 cases, immunological and virological courses, interaction with nutritional status, and response to treatment for COVID-19 patients admitted to treatment centers in Ethiopia.

Methods: This multi-site cohort enrolls, patients with confirmed COVID-19 infection admitted to treatment centers will be enrolled irrespective of their symptoms and followed up for 12 months. Baseline epidemiological, clinical, laboratory and imaging data will be collected from treatment records, interviews, physical measurements and biological samples. Endline data involves treatment and prognostic outcomes to be measured using different biomarkers and clinical parameters, The patients will be followed up in the selected treatment centers for COVID-19 infection. For all data collected both descriptive and multivariable analyses will be performed to isolated determinants of the treatment outcome and prognosis to generate relevant information for informed prevention and case management.

详细描述

Background: The coronavirus disease 2019 (COVID-19) became pandemic after emerging in Wuhan, China, in December 2019 which is caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2). Following the swift spread of the virus,4, 710,000 confirmed cases and 315,000 deaths were reported worldwide as of May 17, 2020,and 317 confirmed cases and 5 deaths are reported nationally. To understand the drastically negative impacts of COVID-19 on the public health and key features pertinent to the disease various researches are under investigation at the global level and they are contributing to delineating the characteristics of the disease and its lethality. However, the potential acceptability of different risks varies depending on numerous factors including the type of research and the context in which it takes place. Currently, it is recognized that a 'one size fits all' approach towards the design and implementation of interventions may not be appropriate. Therefore, it is found apparent that global priorities, protocols and intervention assessments have to be contextualized and adjusted to local needs and realities, including translation of results.

Objective

To determine the epidemiological and clinical features of COVID-19 cases, immunological and virological courses, interaction with nutritional status, and response to treatment for COVID-19 patients admitted to treatment centers in Ethiopia.

Methods: This multi-site cohort enrolls, patients with confirmed COVID-19 infection admitted to treatment centers will be enrolled irrespective of their symptoms and followed up for 12 months. Baseline epidemiological, clinical, laboratory and imaging data will be collected from treatment records, interviews, physical measurements and biological samples. Endline data involves treatment and prognostic outcomes to be measured using different biomarkers and clinical parameters, The patients will be followed up in the selected treatment centers for COVID-19 infection. For all data collected both descriptive and multivariable analyses will be performed to isolated determinants of the treatment outcome and prognosis to generate relevant information for informed prevention and case management.

Expected outcome: The study will generate scientific data for a systematic understanding of natural history, epidemiological characteristics, clinical features and management of COVID-19 that will in turn enables country's health sector to develop strategies to prevent and control the pandemic before it poses further health and socioeconomic crisis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient admitted to treatment centers, with confirmed SARS-CoV-2 infection (virologically confirmed diagnosis by RT-PCR).
  • Agrees to be enrolled in the follow-up study and provide all necessary information/data, blood and nasopharyngeal swab for testing.

排除标准

  • A subject deprived of freedom, subject under a legal protective measure
  • Refusal by participant, parent or appropriate guardian or representative
  • Confirmed diagnosis of other pathogens unrelated to the objectives of this study and no indication or likelihood of co-infection with a relevant pathogen.
  • Participants who will not willing to stay 12 months in the cohort in Ethiopia.
  • Those who are prior involved in the COVID-19 clinical trial or other intervention studies.
  • Not capable of understanding or complying with the study protocol or provide consent
  • Anticipated transfer to another hospital that is not a study site within 72 hours
  • Patients who cannot stand straight due to amputation, kyphosis, scoliosis or paralyzes.

结局指标

主要结局

Number of patients survival or death

时间窗: 12 months

Number patients developing severe infection or death

Rate of recovery time

时间窗: 4 weeks

Mean rate of recovery in patients with diagnosis of COVID-19

Viral shedding

时间窗: 6 weeks

proportion of shedding detected in environment and personal protective equipment

次要结局

  • Viral loads(12 months)
  • Blood pressure(4 weeks)
  • Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19(4 weeks)
  • Assess the prevalence of severe forms among hospitalized patients with cancer and COVID-19(4 weeks)
  • Lipid Profiles(12 months)
  • Clinical symptoms and signs(12 months)
  • Assess the prevalence of nutrient intakes(12 months)
  • Assess the prevalence of micronutrients deficiencies among hospitalized patients with COVID-19(12 months)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Masresha Tessema

Principal Investigator

Ethiopian Public Health Institute

研究点 (1)

Loading locations...

相似试验

Prognostic Factors and Outcomes of COVID-19 Cases in... | 临床试验